The Use and Misuse of GLP-1’s for People with Eating Disorders
The new GLP-1 agonist medications are a live experiment due to the widespread use, and misuse, of these drugs. Here are my most recent observations and recommendations based on reviewing current research, communication with colleagues and clinical observations of patients with eating disorders.
First, the best approach to the medications is to start low and go slow. Some people even need to start at doses lower than recommended by the pharmaceutical company and often stay at very low doses. The benefits of the lower doses are fewer side effects, more longstanding benefit and time for one’s body to adjust to the metabolic changes. Going too fast leads to more side effects, especially nausea and constipation, which can build over months or even years and lead to necessary discontinuation of the drugs. The drugs work best when the intended use is for gastrointestinal hormonal imbalance.
Second, people on these medications need to have normal hunger cues and be able to eat regular meals. When hunger is suppressed, people end up restricting food and losing weight due to having less food than they need. This strategy is never sustainable as anyone knows who has an eating disorder. Food restriction leads to ongoing medical issues and rebound hunger, if not binging, thus perpetuating the binge and restrict cycle.
Third, the medications are ultimately hormonal in nature, not specifically weight loss drugs. They work by affecting hormones and adjusting how the gastrointestinal system works. At doses that are too high, they can lead to food restriction and severe weight loss with no long term benefit. The mentality one uses to approach the GLP-1’s is critical. They are medical interventions to be used judiciously, not miracle weight loss drugs.
Last, it’s very important that people with eating disorders don’t use these drugs to remain at weights lower than their body can manage. The end result is slower GI system, muscle wasting and many other effects of drug-induced anorexia.
These conclusions reflect my current understanding of the guidelines most useful for people with eating disorders considering GLP-1’s. There is no doubt these drugs are here to stay so a thoughtful, curious and cautious approach is necessary to use them safely. More information is on its way in the coming months.